Margaret A. Tempero, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Margaret A. Tempero, MD

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF
Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Phone: (415) 353-9888 (appts)
Box 3211, UCSF
San Francisco, CA 94143-3211

View on UCSF Profiles


Additional Websites


Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology


Professional Experience

  • 1983-1987
    Asst. Prof. of Med., Dept. of Internal Medicine, University of Nebraska Medical Center (UNMC), Omaha, NE
  • 1987-1994
    Associate Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1985
    Assistant Professor (Courtesy), Eppley Institute for Cancer Research, Omaha, NE
  • 1994-1999
    Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1999
    Chief of Oncology/Hematology, V.A. Medical Center, Omaha, NE
  • 1997-1999
    Interim Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1995-1999
    Deputy Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1998-2003
    Member, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 1999-present
    Member, Scientific Advisory Board, Pancreatic Cancer Action Network (PanCAN)
  • 2000- 2007
    Chief of Medical Oncology, UCSF School of Medicine
  • 2000- 2012
    Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2000-present
    Professor of Medicine, UCSF School of Medicine
  • 2003-2004
    President, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 2004-present
    Member, Scientific Advisory Board, V Foundation
  • 2012-present
    Member, Mayo Clinic Annual SPORE Scientific Retreat
  • 2012-present
    Director, UCSF Pancreas Center
  • 2012-present
    Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
  • 2013-present
    Member, External Advisory Board, University of Alabama at Birmingham/University of Minnesota Pancreatic SPORE

Selected Publications

  1. Tempero M. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375.
    View on PubMed
  2. Tempero M. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251.
    View on PubMed
  3. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501.
    View on PubMed
  4. Tempero M. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121.
    View on PubMed
  5. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6.
    View on PubMed
  6. Tempero M. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1.
    View on PubMed
  7. Tempero M. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653.
    View on PubMed
  8. Tempero M. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495.
    View on PubMed
  9. Tempero M. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359.
    View on PubMed
  10. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70.
    View on PubMed
  11. Tempero M. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199.
    View on PubMed
  12. Tempero M. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069.
    View on PubMed
  13. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93.
    View on PubMed
  14. Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953.
    View on PubMed
  15. Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845.
    View on PubMed
  16. Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603.
    View on PubMed
  17. Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449.
    View on PubMed
  18. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  19. Tempero M. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 1; 12(3):301.
    View on PubMed
  20. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed

Go to UCSF Profiles, powered by CTSI